PhRMA fires back in latest drug price exchanges

There has been plenty of angry discourse but little real action around US medicine prices in recent years, but the end of 2018 and the beginning of 2019 are offering evidence of change that is making drug companies sit up and take notice.

In October, the Trump administration  put forward proposals for a new Medicare Part B model using the international pricing index which sent some companies’ share prices in the wrong direction, and then this month the  Democrats proposed sweeping drug price reforms promising 'real and immediate action'.

The same party last week  led the launch of a far-ranging investigation into the drug pricing practices of the US pharmaceutical industry, including sending letters to 12 companies requesting evidence related to their internal processes.